Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a bivalent, live-attenuated veterinary vaccine designed to protect poultry against Newcastle Disease (ND) and Infectious Bronchitis (IB). The vaccine incorporates a thermotolerant stabilizer, which allows the product to maintain potency at ambient temperatures, significantly reducing the reliance on a strict cold chain during distribution in tropical or resource-limited regions. Newcastle Disease is caused by virulent strains of avian paramyxovirus type 1 (Newcastle disease virus), while Infectious Bronchitis is caused by an avian coronavirus (Infectious bronchitis virus). The vaccine typically utilizes attenuated strains such as LaSota for the ND component and H120 for the IB component. It is primarily administered to chickens via intraocular, intranasal, or drinking water routes to stimulate mucosal and systemic immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on newcastle disease and infectious bronchitis vaccine, live, thermotolerant.